BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 24610645)

  • 1. Contribution of ultrasound examination in the detection of neck recurrence in low-risk differentiated thyroid carcinoma patients at first follow-up visits.
    Moslehi M; Assadi M
    Nucl Med Rev Cent East Eur; 2014; 17(1):3-6. PubMed ID: 24610645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E; Aras G; Kucuk NO
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
    Torlontano M; Crocetti U; D'Aloiso L; Bonfitto N; Di Giorgio A; Modoni S; Valle G; Frusciante V; Bisceglia M; Filetti S; Schlumberger M; Trischitta V
    Eur J Endocrinol; 2003 Jan; 148(1):19-24. PubMed ID: 12534353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.
    Frasoldati A; Pesenti M; Gallo M; Caroggio A; Salvo D; Valcavi R
    Cancer; 2003 Jan; 97(1):90-6. PubMed ID: 12491509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
    Rubello D; Mazzarotto R; Casara D
    Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenously labeled thyroid hormones (131I-T3/T4) in sera of patients with differentiated thyroid carcinoma.
    Lukinac L; Franceschi M; Nöthig-Hus D; Lechpammer S; Tomasić J; Vranesić B; Pape E; Kusić Z
    Thyroid; 1996 Jun; 6(3):201-6. PubMed ID: 8837327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
    Ma C; Xie J; Kuang A
    J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups.
    Zakani A; Saghari M; Eftekhari M; Fard-Esfahani A; Fallahi B; Esmaili J; Assadi M
    Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
    Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
    Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer.
    Küçük ON; Gültekin SS; Aras G; Ibiş E
    Nucl Med Commun; 2006 Mar; 27(3):261-6. PubMed ID: 16479246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
    Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
    Ozkan E; Soydal C; Araz M; Aras G; Ibis E
    Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.